Organovo Holdings, Inc. (ONVO)

[TheBuzzard]

Pfizer/Organovo agreement is set to expire at the end of this year.

Organovo Holdings (ONVO.PK): In similar fashion to Lpath above, Organovo may be another one trading below the radar that could start looking like a nice accumulation opportunity as a key catalyst involving Pfizer could unfold over the near term. Organovo, as previously discussed, has developed a 3D printer - the NovoGen MMX Bioprinter - that, in conjunction with regenerative medicine expertise, can generate 'bioprints' of human tissue. In looking at the short to mid term, these prints can be used as disease models to enable more effective therapeutic drug discovery and development, but over the long term the company is looking to apply this technology to generate replacement organs. Given the scope and potential of such a forward-looking technology, Organovo has already landed two major partnerships - one with Pfizer and another with United Therapeutics (UTHR). These deals have already generated over a million dollars for the company's coffers, but the Pfizer relationship is worth watching over the short term as the current agreement is set to expire at the end of this year. That provides a short term catalyst for ONVO shares while the long term potential continues to unfold.

It's also worth noting that Zacks.com initiated coverage of the company with a rating of 'Outperform' and a target price of $3.25 earlier in the year, based on the technology and the company's ability to land high-profile partners. A developing story involving next-generation technology that may be riding under the radar right now.